Long Acting Drugs Market: Technologies and Services, 2023-2035: Distribution by Compatible Dosage Form (Long Acting Injectables, Long Acting Implantable, Long Acting Orals, Long Acting Topicals / Transdermals and Other Dosage Forms), Principle (Manipulation of drug release from delivery systems and Manipulation of in vivo clearance), Strategy (Chemical Modification, Micro-encapsulation, Long Acting Hydrogels, Long Acting Implants, Long Acting Microneedles, Multivesicular Liposomes, Nanocrystal Suspensions and Protein Fusion), Type of Molecule Delivered (Small Molecules, Biologics and Other Molecules), Type of Material Used (Polymer based and Non-polymer based), and Key Geographical Regions (North America, Europe, Asia-Pacific and Middle East and North Africa): Industry Trends and Global Forecasts, 2023-2035
The long acting drug market is likely to grow at a CAGR of 13% during the forecast period 2023-2035.
In recent years, there has been a pronounced shift in the pharmaceutical landscape away from conventional drug delivery methods towards the adoption of long-acting drug delivery systems. These systems offer sustained drug action over extended periods following a single administration, ensuring the maintenance of optimal therapeutic levels within a patient's system for weeks, months, or even years. This transformative transition has significantly impacted various medical domains, including ophthalmology, oncology, neurology, and infectious diseases, presenting promising avenues for treatment.
The adoption of long-acting drug delivery systems brings forth numerous advantages. These include improved patient adherence and compliance, reduced dosing frequency, minimized risks associated with erratic drug usage, and heightened convenience for patients. Additionally, the rise of long-acting vaginal rings as multipurpose prevention technologies for women highlights the expanding scope and demand for such innovations in the medical realm. Integral to the success of these long-acting drug formulations is the meticulous selection of an appropriate dosage form, such as long-acting implants, injectables, vaginal, oral, or topical/transdermal preparations, coupled with strategic implementation of methodologies like micro-encapsulation, nanocrystal suspensions, long-acting hydrogels, and microneedles. This thoughtful amalgamation ensures enhanced drug biodistribution and facilitates targeted therapeutic effects, thereby enabling extended release or duration of action.
Propelled by a relentless pace of innovation in developing these state-of-the-art technologies and driven by a burgeoning market demand for long-acting drug solutions, the long-acting drugs technology and services market is poised for substantial expansion during the forecast period.
Report Coverage
In recent years, there has been a pronounced shift in the pharmaceutical landscape away from conventional drug delivery methods towards the adoption of long-acting drug delivery systems. These systems offer sustained drug action over extended periods following a single administration, ensuring the maintenance of optimal therapeutic levels within a patient's system for weeks, months, or even years. This transformative transition has significantly impacted various medical domains, including ophthalmology, oncology, neurology, and infectious diseases, presenting promising avenues for treatment.
The adoption of long-acting drug delivery systems brings forth numerous advantages. These include improved patient adherence and compliance, reduced dosing frequency, minimized risks associated with erratic drug usage, and heightened convenience for patients. Additionally, the rise of long-acting vaginal rings as multipurpose prevention technologies for women highlights the expanding scope and demand for such innovations in the medical realm. Integral to the success of these long-acting drug formulations is the meticulous selection of an appropriate dosage form, such as long-acting implants, injectables, vaginal, oral, or topical/transdermal preparations, coupled with strategic implementation of methodologies like micro-encapsulation, nanocrystal suspensions, long-acting hydrogels, and microneedles. This thoughtful amalgamation ensures enhanced drug biodistribution and facilitates targeted therapeutic effects, thereby enabling extended release or duration of action.
Propelled by a relentless pace of innovation in developing these state-of-the-art technologies and driven by a burgeoning market demand for long-acting drug solutions, the long-acting drugs technology and services market is poised for substantial expansion during the forecast period.
Report Coverage
- An executive summary of the key insights captured in research. It offers a high-level view on the current state of long-acting drug delivery technologies and services market and its likely evolution in the mid-long term.
- Overview of long-acting drug delivery and types of long-acting drug delivery systems. Additionally, it highlights the underlying principles and strategies associated with long-acting drug delivery.
- Detailed assessment of the current technology landscape of long-acting drug delivery technologies, based on several relevant parameters, such as principle, strategy, type of material used, compatible dosage form(s), extended dosing interval(s), type of molecule(s) delivered, highest phase of development, number of approved drugs and therapeutic area(s).
- Detailed assessment of the overall service providers landscape of the companies offering contract services related to long-acting drug delivery, based on several relevant parameters, such as year of establishment, company size, location of headquarters, location of facilities, type of service provider(s), scale of operation, compatible dosage form(s), service(s) offered and type of molecule(s) supported.
- A detailed technology competitiveness analysis of long-acting drug delivery technologies based on developer power and technology strength.
- A detailed company competitiveness analysis of long-acting drug delivery service providers based on company strength and service strength
- Detailed profiles of prominent (shortlisted based on a proprietary criterion) players developing technologies and offering services in the domain of long-acting drug delivery, across North America, Europe and Asia-Pacific. Each profile features a brief overview of the company, details related to its technology portfolio, service portfolio, recent developments and an informed future outlook.
- A detailed analysis of the recent partnerships inked between stakeholders engaged in this domain, since 2018, covering acquisitions, manufacturing agreements, product development and commercialization agreements, service alliance, technology licensing agreements, and other relevant agreements.
- A detailed analysis of over 570 peer-reviewed, scientific articles on research related to long-acting drug delivery, based on several relevant parameters, such as year of publication, type of publication and popular keywords. It also provides information on top journals, top publishers, top copyright holders and key funding institutes (in terms of number of articles published).
- An insightful analysis of various patents that have been filed / granted related to long-acting drug delivery, since 2018, taking into consideration parameters, such as publication year, geographical region, CPC symbols, type of organization and leading players.
- A detailed review of academic grants that have been awarded to various research institutes for projects focused on long-acting drug delivery, since 2018, based on several parameters, such as year of grant award, amount awarded, support period, type of funding institute center, grant application, purpose of grant award, grant activity code, NIH spending category, study section involved, popular NIH departments and type of recipient organization.
- A comprehensive market forecast and opportunity analysis, highlighting the future potential of the market till the year 2035. We have segregated the current and upcoming opportunity based on principle, strategy, compatible dosage form, type of molecule delivered, type of material used and key geographical regions
- Adare Pharma Solutions
- AMW
- Bostal Drug Delivery
- Creative Biolabs
- ForDoz Pharma
- Innocore Pharmaceuticals
- Integral BioSystems
- LATITUDE Pharmaceuticals
- Navin Saxena Research and Technology Centre (NSRT)
- Samyang Biopharm
1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Long Acting Drug Delivery
3.2.1. Types of Long Acting Drug Delivery Systems
3.3. Long Acting Drug Delivery Technologies
3.3.1. Underlying Principle
3.3.2. Associated Strategies
3.4. Concluding Remarks
4. TECHNOLOGY LANDSCAPE
4.1. Chapter Overview
4.2. Long Acting Drug Delivery: Technology Landscape
4.2.1. Analysis by Principle
4.2.2. Analysis by Strategy
4.2.3. Analysis by Type of Material Used
4.2.4. Analysis by Compatible Dosage Form(s)
4.2.5. Analysis by Extended Dosing Interval(s)
4.2.6. Analysis by Type of Molecule(s) Delivered
4.2.7. Analysis by Highest Phase of Development
4.2.8. Analysis by Number of Approved Drugs
4.2.9. Analysis by Therapeutic Area(s)
4.3. Long Acting Drug Delivery: Technology Developers Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Most Active Players: Analysis by Number of Technologies
5. SERVICE PROVIDERS LANDSCAPE
5.1. Chapter Overview
5.2. Long Acting Drug Delivery: Service Providers Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Company Size and Location of Headquarters
5.2.5. Analysis by Location of Facilities
5.2.6. Analysis by Type of Service Provider(s)
5.2.7. Analysis by Scale of Operation
5.2.8. Analysis by Compatible Dosage Form(s)
5.2.9. Analysis by Scale of Operation and Compatible Dosage Form(s)
5.2.10. Analysis by Service(s) Offered
5.2.11. Analysis by Company Size and Service(s) Offered
5.2.12. Analysis by Year of Establishment, Location of Headquarters and Service(s) Offered
5.2.13. Analysis by Type of Molecule(s) Supported
5.2.14. Analysis by Type of Service Provider(s) and Type of Molecule(s) Supported
6. TECHNOLOGY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Assumptions / Key Parameters
6.3. Methodology
6.4. Technology Competitiveness Analysis
6.4.1. Long Acting Drug Delivery Technologies offered by Small Companies
6.4.2. Long Acting Drug Delivery Technologies offered by Mid-sized Companies
6.4.3. Long Acting Drug Delivery Technologies offered by Large Companies
6.4.4. Long Acting Drug Delivery Technologies offered by Very Large Companies
7. COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Assumptions / Key Parameters
7.3. Methodology
7.4. Company Competitiveness Analysis
7.4.1. Long Acting Drug Delivery Service Providers based in North America
7.4.2. Long Acting Drug Delivery Service Providers based in Europe
7.4.3. Long Acting Drug Delivery Service Providers based in Asia-Pacific
8. COMPANY PROFILES
8.1. Chapter Overview
8.2. Adare Pharma Solutions
8.2.1. Company Overview
8.2.2. Technology Portfolio
8.2.3. Service Portfolio
8.2.4. Recent Developments and Future Outlook
8.3. AMW
8.3.1. Company Overview
8.3.2. Technology Portfolio
8.3.3. Service Portfolio
8.3.4. Recent Developments and Future Outlook
8.4. Bostal Drug Delivery
8.4.1. Company Overview
8.4.2. Technology Portfolio
8.4.3. Service Portfolio
8.4.4. Recent Developments and Future Outlook
8.5. Creative Biolabs
8.5.1. Company Overview
8.5.2. Technology Portfolio
8.5.3. Service Portfolio
8.5.4. Recent Developments and Future Outlook
8.6. ForDoz Pharma
8.6.1. Company Overview
8.6.2. Technology Portfolio
8.6.3. Service Portfolio
8.6.4. Recent Developments and Future Outlook
8.7. InnoCore Pharmaceuticals
8.7.1. Company Overview
8.7.2. Technology Portfolio
8.7.3. Service Portfolio
8.7.4. Recent Developments and Future Outlook
8.8. Integral BioSystems
8.8.1. Company Overview
8.8.2. Technology Portfolio
8.8.3. Service Portfolio
8.8.4. Recent Developments and Future Outlook
8.9. LATITUDE Pharmaceuticals
8.9.1. Company Overview
8.9.2. Technology Portfolio
8.9.3. Service Portfolio
8.9.4. Recent Developments and Future Outlook
8.10. Navin Saxena Research and Technology Centre (NSRT)
8.10.1. Company Overview
8.10.2. Technology Portfolio
8.10.3. Service Portfolio
8.10.4. Recent Developments and Future Outlook
8.11. Samyang Biopharm
8.11.1. Company Overview
8.11.2. Technology Portfolio
8.11.3. Service Portfolio
8.11.4. Recent Developments and Future Outlook
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Long Acting Drug Delivery Technologies and Services: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Analysis by Location of Headquarters of Partner
9.3.6. Analysis by Type of Partnership and Location of Headquarters of Partner
9.3.7. Most Active Players: Analysis by Number of Partnerships
9.3.8. Regional Analysis
9.3.8.1. Intercontinental and Intracontinental Deals
9.3.8.2. Local and International Deals
10. PUBLICATION ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Long Acting Drug Delivery: Publication Analysis
10.3.1. Analysis by Year of Publication
10.3.2. Analysis by Type of Publication
10.3.3. Analysis by Most Popular Keywords
10.3.4. Most Popular Journals: Analysis by Number of Publications
10.3.5. Most Popular Publishers: Analysis by Number of Publications
10.3.6. Most Popular Copyright Holders: Analysis by Number of Publications
10.3.7. Key Funding Institutes: Analysis by Number of Publications
11. PATENT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Long Acting Drug Delivery: Patent Analysis
11.3.1. Analysis by Publication Year
11.3.2. Analysis by Type of Patent and Publication Year
11.3.3. Analysis by Geography
11.3.4. Analysis by CPC Symbols
11.3.5. Leading Industry Players: Analysis by Number of Patents
11.3.6. Analysis by Type of Organization
11.4. Patent Benchmark Analysis
11.4.1. Analysis by Patent Characteristics
11.5. Patent Valuation Analysis
12. GRANT ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Long Acting Drug Delivery: Grant Analysis
12.3.1. Analysis by Year of Grant Award
12.3.2. Analysis by Amount Awarded
12.3.3. Analysis by Support Period
12.3.4. Analysis by Support Period and Funding Institute Center
12.3.5. Analysis by Type of Grant Application
12.3.6. Analysis by Purpose of Grant Award
12.3.7. Analysis By Activity Code
12.3.8. Analysis by NIH Spending Category
12.3.9. Analysis by Study Section Involved
12.3.10. Popular NIH Departments: Analysis by Number of Grants
12.3.11. Analysis by Type of Recipient Organization
12.3.12. Prominent Program Officers: Analysis by Number of Grants
12.3.13. Popular Recipient Organizations: Analysis by Number of Grants
12.3.14. Popular Recipient Organizations: Analysis by Grant Amount
12.3.15. Analysis by Region of Recipient Organizations
13. MARKET FORECAST AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Forecast Methodology
13.3. Global Long Acting Drug Delivery Technologies Market, 2023-2035
13.3.1. Long Acting Drug Delivery Technologies Market: Analysis by Type of Payment Model Employed
13.3.1.1. Long Acting Drug Delivery Technologies Market for Upfront Payment, 2023-2035
13.3.1.2. Long Acting Drug Delivery Technologies Market for Milestone Payment, 2023-2035
13.3.2. Long Acting Drug Delivery Technologies Market: Analysis by Principle
13.3.2.1. Long Acting Drug Delivery Technologies Market for Manipulation of Drug Release from Delivery Systems, 2023-2035
13.3.2.2. Long Acting Drug Delivery Technologies Market for Manipulation of In Vivo Clearance, 2023-2035
13.3.3. Long Acting Drug Delivery Technologies Market: Analysis by Strategy
13.3.3.1. Long Acting Drug Delivery Technologies Market for Micro-encapsulation, 2023-2035
13.3.3.2. Long Acting Drug Delivery Technologies Market for Long Acting Implants, 2023-2035
13.3.3.3. Long Acting Drug Delivery Technologies Market for Multivesicular Liposomes, 2023-2035
13.3.3.4. Long Acting Drug Delivery Technologies Market for Nanocrystal Suspensions, 2023-2035
13.3.3.5. Long Acting Drug Delivery Technologies Market for Long Acting Hydrogels, 2023-2035
13.3.3.6. Long Acting Drug Delivery Technologies Market for Long Acting Microneedles, 2023-2035
13.3.3.7. Long Acting Drug Delivery Technologies Market for Chemical Modification, 2023-2035
13.3.3.8. Long Acting Drug Delivery Technologies Market for Protein Fusion, 2023-2035
13.3.4. Long Acting Drug Delivery Technologies Market: Analysis by Compatible Dosage Form
13.3.4.1. Long Acting Drug Delivery Technologies Market for Injectables, 2023-2035
13.3.4.2. Long Acting Drug Delivery Technologies Market for Implantables, 2023-2035
13.3.4.3. Long Acting Drug Delivery Technologies Market for Vaginal Dosage Forms, 2023-2035
13.3.4.4. Long Acting Drug Delivery Technologies Market for Topical / Transdermal Dosage Forms, 2023-2035
13.3.4.5. Long Acting Drug Delivery Technologies Market for Oral Dosage Forms, 2023-2035
13.3.4.6. Long Acting Drug Delivery Technologies Market for Other Dosage Forms, 2023-2035
13.3.5. Long Acting Drug Delivery Technologies Market: Analysis by Type of Molecule Delivered
13.3.5.1. Long Acting Drug Delivery Technologies Market for Small Molecules, 2023-2035
13.3.5.2. Long Acting Drug Delivery Technologies Market for Biologics, 2023-2035
13.3.5.3. Long Acting Drug Delivery Technologies Market for Other Molecules, 2023-2035
13.3.6. Long Acting Drug Delivery Technologies Market: Analysis by Type of Material Used
13.3.6.1. Long Acting Drug Delivery Technologies Market for Polymer-based, 2023-2035
13.3.6.2. Long Acting Drug Delivery Technologies Market for Non-polymer based, 2023-2035
13.3.7. Long Acting Drug Delivery Technologies Market: Analysis by Region
13.3.7.1. Long Acting Drug Delivery Technologies Market in North America, 2023-2035
13.3.7.2. Long Acting Drug Delivery Technologies Market in Europe, 2023-2035
13.3.7.3. Long Acting Drug Delivery Technologies Market in Asia-Pacific, 2023-2035
13.3.7.4. Long Acting Drug Delivery Technologies Market in Middle East and North Africa, 2023-2035
13.4. Global Long Acting Drug Delivery Services Market, 2023-2035
13.4.1. Long Acting Drug Delivery Services Market: Analysis by Compatible Dosage Form
13.4.1.1. Long Acting Drug Delivery Services Market for Injectables, 2023-2035
13.4.1.2. Long Acting Drug Delivery Services Market for Implantables, 2023-2035
13.4.1.3. Long Acting Drug Delivery Services Market for Vaginal Dosage Forms, 2023-2035
13.4.1.4. Long Acting Drug Delivery Services Market for Topical / Transdermal Dosage Forms, 2023-2035
13.4.1.5. Long Acting Drug Delivery Services Market for Oral Dosage Forms, 2023-2035
13.4.1.6. Long Acting Drug Delivery Services Market for Other Dosage Forms, 2023-2035
13.4.2. Long Acting Drug Delivery Services Market: Analysis by Type of Molecule Supported
13.4.2.1. Long Acting Drug Delivery Services Market for Small Molecules, 2023-2035
13.4.2.2. Long Acting Drug Delivery Services Market for Biologics, 2023-2035
13.4.2.3. Long Acting Drug Delivery Services Market for Other Molecules, 2023-2035
13.4.3. Long Acting Drug Delivery Services Market: Analysis by Region
13.4.3.1. Long Acting Drug Delivery Services Market in North America, 2023-2035
13.4.3.2. Long Acting Drug Delivery Services Market in Europe, 2023-2035
13.4.3.3. Long Acting Drug Delivery Services Market in Asia-Pacific, 2023-2035
14. CONCLUSION
15. INTERVIEW TRANSCRIPTS
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Long Acting Drug Delivery
3.2.1. Types of Long Acting Drug Delivery Systems
3.3. Long Acting Drug Delivery Technologies
3.3.1. Underlying Principle
3.3.2. Associated Strategies
3.4. Concluding Remarks
4. TECHNOLOGY LANDSCAPE
4.1. Chapter Overview
4.2. Long Acting Drug Delivery: Technology Landscape
4.2.1. Analysis by Principle
4.2.2. Analysis by Strategy
4.2.3. Analysis by Type of Material Used
4.2.4. Analysis by Compatible Dosage Form(s)
4.2.5. Analysis by Extended Dosing Interval(s)
4.2.6. Analysis by Type of Molecule(s) Delivered
4.2.7. Analysis by Highest Phase of Development
4.2.8. Analysis by Number of Approved Drugs
4.2.9. Analysis by Therapeutic Area(s)
4.3. Long Acting Drug Delivery: Technology Developers Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Most Active Players: Analysis by Number of Technologies
5. SERVICE PROVIDERS LANDSCAPE
5.1. Chapter Overview
5.2. Long Acting Drug Delivery: Service Providers Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Company Size and Location of Headquarters
5.2.5. Analysis by Location of Facilities
5.2.6. Analysis by Type of Service Provider(s)
5.2.7. Analysis by Scale of Operation
5.2.8. Analysis by Compatible Dosage Form(s)
5.2.9. Analysis by Scale of Operation and Compatible Dosage Form(s)
5.2.10. Analysis by Service(s) Offered
5.2.11. Analysis by Company Size and Service(s) Offered
5.2.12. Analysis by Year of Establishment, Location of Headquarters and Service(s) Offered
5.2.13. Analysis by Type of Molecule(s) Supported
5.2.14. Analysis by Type of Service Provider(s) and Type of Molecule(s) Supported
6. TECHNOLOGY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Assumptions / Key Parameters
6.3. Methodology
6.4. Technology Competitiveness Analysis
6.4.1. Long Acting Drug Delivery Technologies offered by Small Companies
6.4.2. Long Acting Drug Delivery Technologies offered by Mid-sized Companies
6.4.3. Long Acting Drug Delivery Technologies offered by Large Companies
6.4.4. Long Acting Drug Delivery Technologies offered by Very Large Companies
7. COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Assumptions / Key Parameters
7.3. Methodology
7.4. Company Competitiveness Analysis
7.4.1. Long Acting Drug Delivery Service Providers based in North America
7.4.2. Long Acting Drug Delivery Service Providers based in Europe
7.4.3. Long Acting Drug Delivery Service Providers based in Asia-Pacific
8. COMPANY PROFILES
8.1. Chapter Overview
8.2. Adare Pharma Solutions
8.2.1. Company Overview
8.2.2. Technology Portfolio
8.2.3. Service Portfolio
8.2.4. Recent Developments and Future Outlook
8.3. AMW
8.3.1. Company Overview
8.3.2. Technology Portfolio
8.3.3. Service Portfolio
8.3.4. Recent Developments and Future Outlook
8.4. Bostal Drug Delivery
8.4.1. Company Overview
8.4.2. Technology Portfolio
8.4.3. Service Portfolio
8.4.4. Recent Developments and Future Outlook
8.5. Creative Biolabs
8.5.1. Company Overview
8.5.2. Technology Portfolio
8.5.3. Service Portfolio
8.5.4. Recent Developments and Future Outlook
8.6. ForDoz Pharma
8.6.1. Company Overview
8.6.2. Technology Portfolio
8.6.3. Service Portfolio
8.6.4. Recent Developments and Future Outlook
8.7. InnoCore Pharmaceuticals
8.7.1. Company Overview
8.7.2. Technology Portfolio
8.7.3. Service Portfolio
8.7.4. Recent Developments and Future Outlook
8.8. Integral BioSystems
8.8.1. Company Overview
8.8.2. Technology Portfolio
8.8.3. Service Portfolio
8.8.4. Recent Developments and Future Outlook
8.9. LATITUDE Pharmaceuticals
8.9.1. Company Overview
8.9.2. Technology Portfolio
8.9.3. Service Portfolio
8.9.4. Recent Developments and Future Outlook
8.10. Navin Saxena Research and Technology Centre (NSRT)
8.10.1. Company Overview
8.10.2. Technology Portfolio
8.10.3. Service Portfolio
8.10.4. Recent Developments and Future Outlook
8.11. Samyang Biopharm
8.11.1. Company Overview
8.11.2. Technology Portfolio
8.11.3. Service Portfolio
8.11.4. Recent Developments and Future Outlook
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Long Acting Drug Delivery Technologies and Services: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Analysis by Location of Headquarters of Partner
9.3.6. Analysis by Type of Partnership and Location of Headquarters of Partner
9.3.7. Most Active Players: Analysis by Number of Partnerships
9.3.8. Regional Analysis
9.3.8.1. Intercontinental and Intracontinental Deals
9.3.8.2. Local and International Deals
10. PUBLICATION ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Long Acting Drug Delivery: Publication Analysis
10.3.1. Analysis by Year of Publication
10.3.2. Analysis by Type of Publication
10.3.3. Analysis by Most Popular Keywords
10.3.4. Most Popular Journals: Analysis by Number of Publications
10.3.5. Most Popular Publishers: Analysis by Number of Publications
10.3.6. Most Popular Copyright Holders: Analysis by Number of Publications
10.3.7. Key Funding Institutes: Analysis by Number of Publications
11. PATENT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Long Acting Drug Delivery: Patent Analysis
11.3.1. Analysis by Publication Year
11.3.2. Analysis by Type of Patent and Publication Year
11.3.3. Analysis by Geography
11.3.4. Analysis by CPC Symbols
11.3.5. Leading Industry Players: Analysis by Number of Patents
11.3.6. Analysis by Type of Organization
11.4. Patent Benchmark Analysis
11.4.1. Analysis by Patent Characteristics
11.5. Patent Valuation Analysis
12. GRANT ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Long Acting Drug Delivery: Grant Analysis
12.3.1. Analysis by Year of Grant Award
12.3.2. Analysis by Amount Awarded
12.3.3. Analysis by Support Period
12.3.4. Analysis by Support Period and Funding Institute Center
12.3.5. Analysis by Type of Grant Application
12.3.6. Analysis by Purpose of Grant Award
12.3.7. Analysis By Activity Code
12.3.8. Analysis by NIH Spending Category
12.3.9. Analysis by Study Section Involved
12.3.10. Popular NIH Departments: Analysis by Number of Grants
12.3.11. Analysis by Type of Recipient Organization
12.3.12. Prominent Program Officers: Analysis by Number of Grants
12.3.13. Popular Recipient Organizations: Analysis by Number of Grants
12.3.14. Popular Recipient Organizations: Analysis by Grant Amount
12.3.15. Analysis by Region of Recipient Organizations
13. MARKET FORECAST AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Forecast Methodology
13.3. Global Long Acting Drug Delivery Technologies Market, 2023-2035
13.3.1. Long Acting Drug Delivery Technologies Market: Analysis by Type of Payment Model Employed
13.3.1.1. Long Acting Drug Delivery Technologies Market for Upfront Payment, 2023-2035
13.3.1.2. Long Acting Drug Delivery Technologies Market for Milestone Payment, 2023-2035
13.3.2. Long Acting Drug Delivery Technologies Market: Analysis by Principle
13.3.2.1. Long Acting Drug Delivery Technologies Market for Manipulation of Drug Release from Delivery Systems, 2023-2035
13.3.2.2. Long Acting Drug Delivery Technologies Market for Manipulation of In Vivo Clearance, 2023-2035
13.3.3. Long Acting Drug Delivery Technologies Market: Analysis by Strategy
13.3.3.1. Long Acting Drug Delivery Technologies Market for Micro-encapsulation, 2023-2035
13.3.3.2. Long Acting Drug Delivery Technologies Market for Long Acting Implants, 2023-2035
13.3.3.3. Long Acting Drug Delivery Technologies Market for Multivesicular Liposomes, 2023-2035
13.3.3.4. Long Acting Drug Delivery Technologies Market for Nanocrystal Suspensions, 2023-2035
13.3.3.5. Long Acting Drug Delivery Technologies Market for Long Acting Hydrogels, 2023-2035
13.3.3.6. Long Acting Drug Delivery Technologies Market for Long Acting Microneedles, 2023-2035
13.3.3.7. Long Acting Drug Delivery Technologies Market for Chemical Modification, 2023-2035
13.3.3.8. Long Acting Drug Delivery Technologies Market for Protein Fusion, 2023-2035
13.3.4. Long Acting Drug Delivery Technologies Market: Analysis by Compatible Dosage Form
13.3.4.1. Long Acting Drug Delivery Technologies Market for Injectables, 2023-2035
13.3.4.2. Long Acting Drug Delivery Technologies Market for Implantables, 2023-2035
13.3.4.3. Long Acting Drug Delivery Technologies Market for Vaginal Dosage Forms, 2023-2035
13.3.4.4. Long Acting Drug Delivery Technologies Market for Topical / Transdermal Dosage Forms, 2023-2035
13.3.4.5. Long Acting Drug Delivery Technologies Market for Oral Dosage Forms, 2023-2035
13.3.4.6. Long Acting Drug Delivery Technologies Market for Other Dosage Forms, 2023-2035
13.3.5. Long Acting Drug Delivery Technologies Market: Analysis by Type of Molecule Delivered
13.3.5.1. Long Acting Drug Delivery Technologies Market for Small Molecules, 2023-2035
13.3.5.2. Long Acting Drug Delivery Technologies Market for Biologics, 2023-2035
13.3.5.3. Long Acting Drug Delivery Technologies Market for Other Molecules, 2023-2035
13.3.6. Long Acting Drug Delivery Technologies Market: Analysis by Type of Material Used
13.3.6.1. Long Acting Drug Delivery Technologies Market for Polymer-based, 2023-2035
13.3.6.2. Long Acting Drug Delivery Technologies Market for Non-polymer based, 2023-2035
13.3.7. Long Acting Drug Delivery Technologies Market: Analysis by Region
13.3.7.1. Long Acting Drug Delivery Technologies Market in North America, 2023-2035
13.3.7.2. Long Acting Drug Delivery Technologies Market in Europe, 2023-2035
13.3.7.3. Long Acting Drug Delivery Technologies Market in Asia-Pacific, 2023-2035
13.3.7.4. Long Acting Drug Delivery Technologies Market in Middle East and North Africa, 2023-2035
13.4. Global Long Acting Drug Delivery Services Market, 2023-2035
13.4.1. Long Acting Drug Delivery Services Market: Analysis by Compatible Dosage Form
13.4.1.1. Long Acting Drug Delivery Services Market for Injectables, 2023-2035
13.4.1.2. Long Acting Drug Delivery Services Market for Implantables, 2023-2035
13.4.1.3. Long Acting Drug Delivery Services Market for Vaginal Dosage Forms, 2023-2035
13.4.1.4. Long Acting Drug Delivery Services Market for Topical / Transdermal Dosage Forms, 2023-2035
13.4.1.5. Long Acting Drug Delivery Services Market for Oral Dosage Forms, 2023-2035
13.4.1.6. Long Acting Drug Delivery Services Market for Other Dosage Forms, 2023-2035
13.4.2. Long Acting Drug Delivery Services Market: Analysis by Type of Molecule Supported
13.4.2.1. Long Acting Drug Delivery Services Market for Small Molecules, 2023-2035
13.4.2.2. Long Acting Drug Delivery Services Market for Biologics, 2023-2035
13.4.2.3. Long Acting Drug Delivery Services Market for Other Molecules, 2023-2035
13.4.3. Long Acting Drug Delivery Services Market: Analysis by Region
13.4.3.1. Long Acting Drug Delivery Services Market in North America, 2023-2035
13.4.3.2. Long Acting Drug Delivery Services Market in Europe, 2023-2035
13.4.3.3. Long Acting Drug Delivery Services Market in Asia-Pacific, 2023-2035
14. CONCLUSION
15. INTERVIEW TRANSCRIPTS
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
